Vimarsana
Biggest News Aggregation in the World

Monitoring Recommendations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Monitoring Recommendations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Monitoring Recommendations Today - Breaking & Trending Today

FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19 - Vimarsana News

FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority...

New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19 - Vimarsana News

New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection - Vimarsana News

UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19 - Vimarsana News

Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19

Press release content from PR Newswire. The AP news staff was not involved in its creation. Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19 July 20, 2021 GMT TARRYTOWN, N.Y., July 20, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Regeneron’s casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate COVID-19. This marks the first time the antibody cocktail, known ...

Source: apnews.com
FDA Authorizes Lower 1,200 mg Intravenous and Subcutaneous Dose of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail to Treat Patients with COVID-19 - Vimarsana News

FDA Authorizes Lower 1,200 mg Intravenous and Subcutaneous Dose of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail to Treat Patients with COVID-19

/PRNewswire/ -- EUA supported by pivotal Phase 3 data showing 1,200 mg dose reduced risk of hospitalization or death by 70% Only antibody therapy currently...